01—Abstract
Summary
Summary of the 8-K filed June 3, 2019. Cited figures are marked; the original filing is the authoritative source.
Moderna, Inc. (MRNA) filed an 8-K on June 3, 2019, to disclose interim data from a Phase 1 study of its personalized cancer vaccine (PCV), mRNA-4157.
The data was presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. While details within this 8-K are limited, it directs investors to furnished exhibits (press release and presentation slides) for a comprehensive understanding of the trial results. This filing is crucial as it provides early-stage clinical insights into one of Moderna's key pipeline candidates.
02—Key points
Key Highlights
- Moderna presented interim Phase 1 data for its personalized cancer vaccine (PCV), mRNA-4157, at the 2019 ASCO Annual Meeting.
- The filing includes furnished exhibits: a press release (Exhibit 99.1) and presentation slides (Exhibit 99.2) detailing the study results.
- The National Cancer Institute (NCI) also presented early data from its Phase 1 study of mRNA-4650, which utilizes Moderna's mRNA technology.
- Early data for mRNA-4650 indicated safety at studied dose levels with no dose-limiting toxicities or related grade 3/4 adverse events.
- NCI observed neoantigen-specific T-cell responses in three out of four patients evaluated in the mRNA-4650 study.
- The NCI's mRNA-4650 program uses a different neoantigen selection process and study design compared to Moderna's mRNA-4157 study.
03—Questions
Frequently Asked Questions
What is the main purpose of this 8-K filing?
The main purpose of this 8-K filing is to publicly disclose interim data from Moderna's Phase 1 study of its personalized cancer vaccine (mRNA-4157) and early data from the National Cancer Institute's (NCI) study of mRNA-4650, both presented at the 2019 ASCO Annual Meeting. It also furnishes the associated press release and presentation slides for investor review.
Where can I find the detailed results of the mRNA-4157 study?
Detailed results for the mRNA-4157 study are not fully included within the 8-K filing itself. Investors are directed to the furnished exhibits, specifically Exhibit 99.1 (Press Release) and Exhibit 99.2 (ASCO Presentation Slides), for comprehensive information on the interim Phase 1 data.
What is the difference between mRNA-4157 and mRNA-4650?
mRNA-4157 is Moderna's personalized cancer vaccine (PCV) being studied in its own Phase 1 trial. mRNA-4650 is also a cancer vaccine utilizing Moderna's mRNA technology, but it's being developed and studied by the National Cancer Institute (NCI) with a different neoantigen selection process and study design than mRNA-4157.
What were the key findings regarding the safety of mRNA-4650?
Early data presented by the NCI for mRNA-4650 indicated that the vaccine was safe at the studied dose levels (0.13 and 0.39 mg). There were no reported dose-limiting toxicities and no related grade 3 or 4 adverse events or serious adverse events observed in the patients evaluated.
04—Continue